drugset / Trial / NCT04738175
Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19
RandomizedParallel-groupTriple-blindTreatment
Summary
Subjects will receive a single injection of 40, 100, or 200 mg COVI-AMG or placebo via IV push.
Timeline
- Start
- 2021-04
- Primary completion
- 2021-11
- Completion
- 2021-11
Outcome
Outcome not reported
Stopped: “A different study will be conducted.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PLUTAVIMAB | Monoclonal antibody | 40 mg | Intravenous |
| Subject | PLUTAVIMAB | Monoclonal antibody | 100 mg | Intravenous |
| Subject | PLUTAVIMAB | Monoclonal antibody | 200 mg | Intravenous |